Scientists Identify New Vulnerability in Treatment-Resistant Prostate Cancer
Prostate cancer is one of the most common cancers affecting men worldwide, and while many cases respond well to initial treatments, a significant number develop resistance over time. When this happens, the cancer can become especially difficult to treat.
A key mechanism behind this resistance involves what researchers call lineage plasticity—the cancer's ability to change its cellular identity. Prostate tumors that become treatment-resistant often shift from typical prostate cell characteristics toward a neuroendocrine-like state, allowing them to survive therapies that would otherwise destroy them.
Scientists have now identified a potential way to exploit this very mechanism. In preclinical experiments, researchers combined two distinct classes of drugs that, together, reversed many of these cellular changes. This drug combination sharply slowed tumor growth compared to standard approaches.
The findings offer a possible new strategy for addressing aggressive, treatment-resistant prostate cancer. By targeting the cancer's ability to reprogram itself rather than simply attacking the cancer cells directly, researchers believe this approach could eventually provide a new therapeutic option for patients who have exhausted conventional treatments. Further studies are needed before clinical applications can be explored.